Georg F. Baur
Direktor/Vorstandsmitglied bei HEIDELBERG PHARMA AG
Ursprung des Netzwerks ersten Grades von Georg F. Baur
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 27 | |
J.P. Morgan SE
 J.P. Morgan SE Major BanksFinance Part of JPMorgan Chase & Co., J.P. Morgan SE is a German commercial banking company. The company is based in Frankfurt, Germany. The CEOs are Stefan Behr, Patrik Czornik. The company was founded in 1928.
3
| Subsidiary | Major Banks | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Georg F. Baur
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Molecular Health GmbH
 Molecular Health GmbH Miscellaneous Commercial ServicesCommercial Services Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004. | Miscellaneous Commercial Services | Chief Executive Officer Chairman Director/Board Member | |
| dievini Verwaltungs GmbH | Chief Executive Officer Chief Executive Officer Chief Executive Officer | ||
| Ludwig-Maximilians-Universität München | College/University | Graduate Degree Doctorate Degree Doctorate Degree | |
Wilex, Inc.
 Wilex, Inc. Medical/Nursing ServicesHealth Services Part of Nuclea Biotechnologies, Inc., Wilex, Inc. develops medical diagnostic tests. The company is based in Cambridge, MA. The CEOs of the company are Thomas Borcholte, Olaf G. Wilhelm. Wilex was acquired by Nuclea Biotechnologies, Inc. from Heidelberg Pharma AG on September 06, 2013. | Medical/Nursing Services | Chief Executive Officer Director of Finance/CFO Chief Executive Officer | |
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Biotechnology | Chairman Director/Board Member Director/Board Member | |
Molecular Health, Inc.
 Molecular Health, Inc. Packaged SoftwareTechnology Services Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA. | Packaged Software | Chairman Director/Board Member Director/Board Member | |
| AC IMMUNE SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
BIO Deutschland
 BIO Deutschland Miscellaneous Commercial ServicesCommercial Services BIO Deutschland is a business association for the biotechnology industry. The private company is based in Berlin, Germany. The German company was founded by Peter Heinrich, Horst Domdey. Viola Bronsema has been the CEO of the company since 2006. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Director of Finance/CFO | |
dievini Hopp BioTech holding GmbH & Co. KG
 dievini Hopp BioTech holding GmbH & Co. KG Investment ManagersFinance dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany. | Investment Managers | Private Equity Investor Founder Chief Executive Officer | |
| 2INVEST AG | Financial Conglomerates | Director/Board Member Director/Board Member Director/Board Member | |
| IMMATICS N.V. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| Febit, Inc. | Director/Board Member Chairman | ||
| MORPHOSYS AG | Biotechnology | Human Resources Officer General Counsel | |
Novaliq GmbH
 Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Medical Specialties | Chairman Director/Board Member | |
febit holding GmbH
 febit holding GmbH Medical/Nursing ServicesHealth Services febit holding GmbH engages in the design and development of technologies used for DNA analysis. It specializes in technologies with applications in genomic research, RNA expression profiling, and other diagnostic and molecular biology fields. The company was founded by Markus Beier, Ramon Gueimil, Peer F. Staehler, Matthias Scheffler, and Cord F. Stähler in 2005 and is headquartered in Heidelberg, Germany. | Medical/Nursing Services | Director/Board Member Chairman | |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Biotechnology | Director/Board Member Director/Board Member | |
| FRESENIUS SE & CO. KGAA | Medical Specialties | Corporate Officer/Principal Director/Board Member | |
| CUREVAC N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Heidelberg Pharma Research GmbH
 Heidelberg Pharma Research GmbH Miscellaneous Commercial ServicesCommercial Services Part of Heidelberg Pharma AG, Heidelberg Pharma Research GmbH is a German company that engages in researching biotechnology. The company is based in Ladenburg, Germany. The company was founded in 2011. Andreas Pahl has been the CEO of the company since 2012. | Miscellaneous Commercial Services | Chief Executive Officer Chief Executive Officer | |
| University of Mannheim | College/University | Doctorate Degree Undergraduate Degree | |
RITTERSHAUS Rechtsanwälte Partnerschaftsgesellschaft mbB
 RITTERSHAUS Rechtsanwälte Partnerschaftsgesellschaft mbB Miscellaneous Commercial ServicesCommercial Services RITTERSHAUS Rechtsanwälte Partnerschaftsgesellschaft mbB is a law firm based in Mannheim, Germany. The German company has a unique perspective on the legal world and operates differently from traditional law firms. The private company's description emphasizes its distinctiveness and alternative approach to legal services. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| BASF SE | Electrical Products | Corporate Officer/Principal Corporate Officer/Principal | |
LTS LOHMANN Therapie-Systeme AG
 LTS LOHMANN Therapie-Systeme AG Pharmaceuticals: MajorHealth Technology LTS LOHMANN Therapie-Systeme AG manufactures transdermal therapeutic systems and oral thin films. The firm's product range encompasses oral active ingredient films, nicotine patches, and pharmaceutical drugs in dosage forms. Its service areas cover clinical trials, laboratory testing, and research and development projects. The company was founded in 1984 and is headquartered in Andernach, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal Chairman | |
| University of Freiburg | College/University | Graduate Degree | |
UCB Pharma GmbH
 UCB Pharma GmbH Pharmaceuticals: MajorHealth Technology UCB Pharma GmbH manufactures and develops drugs. It manufactures prescription and non-prescription drugs. With its partners, the company engages in biopharmaceutical research and development. Apart from providing medication, the company provides support to the patients. The company was founded in 1928 and is headquartered in Monheim, Germany. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Bohlini GmbH & Co. KG | President | ||
| Hoechst Marion Roussel, Inc. | Chief Tech/Sci/R&D Officer | ||
Transcelerate Biopharma, Inc.
 Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Biotechnology | Chairman | |
| EVOTEC SE | Pharmaceuticals: Major | Chairman | |
| Bohlini Verwaltungs GmbH | President | ||
| Johann Wolfgang Goethe-Universität Frankfurt am Main | College/University | Corporate Officer/Principal | |
SRH Holding (SdbR)
 SRH Holding (SdbR) Other Consumer ServicesConsumer Services SRH Holding engages in the provision of educational and health care services. It operates universities, vocational schools, vocational rehabilitation centers, acute care hospitals, rehabilitation clinics, and outpatient care centers. The company was founded in 1966 and is headquartered in Heidelberg, Germany. | Other Consumer Services | Chief Executive Officer | |
| UCB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| BASF Pharma | Corporate Officer/Principal | ||
Franz Haniel & Cie. GmbH
 Franz Haniel & Cie. GmbH Investment ManagersFinance Franz Haniel & Cie. GmbH is a Haniel family equity firm. The company was founded in 1756 by Jan Willem Noot and is headquartered in Duisburg, Germany. | Investment Managers | Director/Board Member | |
Rottendorf Pharma GmbH
 Rottendorf Pharma GmbH Pharmaceuticals: MajorHealth Technology Part of Rottendorf-Stiftung, Rottendorf Pharma GmbH is a German company that engages in manufacturing, packaging, developing formulations and analytical methods for solid oral dosage forms for the pharmaceutical industry. The company is based in Ennigerloh, Germany. The company was founded in 1928 by Andreas J. Rottendorf. The CEO is Stephan Fleck. | Pharmaceuticals: Major | Director/Board Member | |
Mundipharma International Ltd.
 Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Mundipharma International Ltd. develops and produces pharmaceutical products. It offers analgesics, oncology, respiratory, gastrointestinal, and cardiovascular drugs. The company was founded in 1952 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
J.F. Müller & Sohn AG
 J.F. Müller & Sohn AG Forest ProductsNon-Energy Minerals J.F. Müller & Sohn AG manufactures hardwood veneer, softwood veneer, and plywood. The company was founded by Friedrich Jacob Müller in 1795 and is headquartered in Hamburg, Germany. | Forest Products | Chairman | |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Chairman | |
SRH Higher Education GmbH
 SRH Higher Education GmbH Miscellaneous Commercial ServicesCommercial Services SRH Higher Education GmbH engages in the operation of universities. It aims to promote vocational training, science, and research. The firm also has the objective of promoting the public health system and public healthcare, welfare services for young people and the elderly, general education, and social welfare. The company is headquartered in Heidelberg, Germany. | Miscellaneous Commercial Services | Chief Executive Officer | |
| WIRECARD AG | Regional Banks | Chairman | |
| Aventis Pharma AG | Corporate Officer/Principal |
Statistik
International
| Deutschland | 40 |
| Vereinigte Staaten | 7 |
| Belgien | 3 |
| Schweiz | 2 |
| Niederlande | 2 |
Sektoral
| Health Technology | 21 |
| Commercial Services | 9 |
| Consumer Services | 6 |
| Finance | 5 |
| Health Services | 3 |
Operativ
| Director/Board Member | 118 |
| Corporate Officer/Principal | 54 |
| Chairman | 49 |
| Chief Executive Officer | 41 |
| Doctorate Degree | 19 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Christof Hettich | 40 |
| Friedrich von Bohlen und Halbach | 36 |
| David Ebsworth | 26 |
| Mathias Hothum | 19 |
| Iris Löw-Friedrich | 15 |
| Marinos Yannopoulos | 14 |
| Alexandra Goll | 14 |
| Peter Llewellyn-Davies | 14 |
| Andreas Krebs | 13 |
| Wulf Matthias | 12 |
| Thomas Borcholte | 11 |
| Birgit Kudlek | 11 |
| Martin Bürmann | 10 |
| Andreas Pahl | 9 |
| Jan Schmidt-Brand | 9 |
- Börse
- Insiders
- Georg F. Baur
- Unternehmensverbindungen
